Skip to content
Screener

McKesson MCK D&A

Discontinued — last reported Q3 '20

D&A at other companies

Cencora logo
CencoraCOR
$118.54M-5.8%
TOI
TOITOI
$1.62M-9.4%
Medline, Inc. logo
Medline, Inc.MDLN
$256M+2.4%
GoodRx Holdings, Inc. logo
GoodRx Holdings, Inc.GDRX
$22.27M+12.9%
CVS Health logo
CVS HealthCVS
$1.13B-3.8%
Baxter International logo
Baxter InternationalBAX
$237M-4.0%

Segments

By segment

See full
Oncology & Multispecialty$66M—
North American Pharmaceutical$39M—
Medical-Surgical Solutions$26M+18.2%
Prescription Technology Solutions$19M-9.5%

Other financials

Income statement

See full
Revenue$105.38B+7.7%
Gross profit$3.7B+12.4%
Operating income$1.3B+27.3%
Net income$614.0M-21.7%
EPS (diluted)$5.15-17.6%

Balance sheet

See full
Cash & equivalents$5.3B+95.9%
Total debt$13.0B+15.7%
Total equity-$4.2B-116%
Total assets$88.3B+8.6%

Cash flow

See full
Operating cash flow-$220.0M+76.0%
CapEx$112.0M+0.9%
Free cash flow-$332.0M+67.7%

Valuation

See full
Market cap$101.59B+15.6%
Enterprise value$109.31B+13.4%
P/E22.1×-5.7×
P/S0.3×0.0×

Profitability

See full
Gross margin3.6%+0.1pp
Operating margin1.6%+0.4pp
Net margin1.1%+0.3pp
FCF margin1.6%0.0pp

Returns & leverage

See full
Return on equity36%—
Debt / equity2×—
Current ratio0.9×0.0×

Where this comes from

Reported directly by McKesson in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The source filing: McKesson’s 10-Q, filed February 4, 2020. Open the filing →

Filed
Feb 3, 2020, 7:00 PM EST
Fiscal quarter
Q3 FY2020
Calendar quarter
Q4 2019
Accession
0000927653-20-000016

FAQ

What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.